This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Hodgkin's disease
  • /
  • Antigenic modulation limits the efficacy of anti-C...

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

Read time: 1 mins
Published:24th Jun 2010
Author: Beers SA, French RR, Chan HT, Lim SH, Jarrett TC, Vidal RM, et al.
Source: Blood
Availability: Free full text
Ref.:Blood. 2010 Jun 24;115(25):5191-201.

Rituximab, a monoclonal antibody that targets CD20 on B cells, is now central to the treatment of a variety of malignant and autoimmune disorders. Despite this success, a substantial proportion of B-cell lymphomas are unresponsive or develop resistance, hence more potent anti-CD20 monoclonal antibodies (mAbs) are continuously being sought. Here we demonstrate that type II (tositumomab-like) anti-CD20 mAbs are 5 times more potent than type I (rituximab-like) reagents in depleting human CD20 Tg B cells, despite both operating exclusively via activatory Fcgamma receptor-expressing macrophages. Much of this disparity in performance is attributable to type I mAb-mediated internalization of CD20 by B cells, leading to reduced macrophage recruitment and the degradation of CD20/mAb complexes, shortening mAb half-life. Importantly, human B cells from healthy donors and most cases of chronic lymphatic leukemia and mantle cell lymphoma, showed rapid CD20 internalization that paralleled that seen in the Tg mouse B cells, whereas most follicular lymphoma and diffuse large B-cell lymphoma cells were far more resistant to CD20 loss. We postulate that differences in CD20 modulation may play a central role in determining the relative efficacy of rituximab in treating these diseases and strengthen the case for focusing on type II anti-CD20 mAb in the clinic.

Read abstract on library site

Access full article